Form 990 for tax year 2022
Filed by UNITED STATES ADULT CYSTIC FIBROSIS ASSOCIATION.
Totals
- Total revenue
- $94,318
- Total expenses
- $64,105
- Contributions and grants received
- $91,089
- Grants paid
- $17,500
- Program service revenue
- $0
- Investment income
- $3,229
- Other revenue
- $0
- Total assets, end of year
- $790,878
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $790,878
- Program services expenses (Part IX)
- $64,105
- Management and general expenses
- $0
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $64,105
Program services were 100.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Listed in Part VII
-
COLLEEN ADAMSON
Treasurer
- Total calculated
- $0
- Hours/week
- 2
-
BETH SUFIAN
Vice President
- Total calculated
- $0
- Hours/week
- 2
-
GABRIELA CASTILLO
Director
- Total calculated
- $0
- Hours/week
- 2
-
SYDNA MARSHALL
President
- Total calculated
- $0
- Hours/week
- 2
-
ANDREA EISENMAN
EXE EDITOR
- Total calculated
- $0
- Hours/week
- 2
-
XAN NOWAKOWSKI
Director
- Total calculated
- $0
- Hours/week
- 2
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 6 May 2023
- IRS schema version
- 2022v5.0
- Source object
- 202301279349300000
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.